Pharmaceuticals, Biotechnology and Life Sciences
Abzena Thrusday announced a new round of investment. Funding sources for the additional $65 million include majority-owner Welsh, Carson, Anderson & Stowe (WCAS), Biospring Partners, and other affiliated investors.
Abzena, a partner research organization for integrated services from discovery through to clinical and commercial manufacturing for biologics and bioconjugates,…
PRINCETON, N.J. & SAN DIEGO–(BUSINESS WIRE)–Sonnet BioTherapeutics Inc., a clinical stage biopharmaceutical developing innovative targeted biologic drugs, announced today that…
SAN DIEGO, Calif.–(BUSINESS WIRE)–Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive…
Abzena, the leading global biologics and ADC target partner research organization, announced it has appointed Andrew Kraus as Chief Technology Officer (CTO) and Philip Payne as Chief Commercial Officer (CCO).
CAMBRIDGE, England & San Diego–(BUSINESS WIRE)–Abzena, the leading global biologics target to GMP partner research organisation, announced it has appointed…
CAMBRIDGE, England–(BUSINESS WIRE)–Abzena, the leading biologics target to GMP partner research organisation (PRO), announced its Cambridge UK site has brought…
SAN DIEGO, Calif.–(BUSINESS WIRE)–Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to…
Abzena has settled with Stanford University about the claims against PacificGMP.
Abzena, a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, will initiate a placing to raise approximately £25 million to expand further its service offering, capacity and capabilities.